Source comparison
BPC-157 vs Cartalax: Research Comparison
The following table compares key research parameters for BPC-157 and Cartalax to guide experimental design decisions. Primary Mechanism Angiogenesis, VEGF/FGF upregulation, NO pathway modulation Gene expression normalization, ribosomal RNA synthesis, protein r
This comparison does not assign a generated winner or score.
- The following table compares key research parameters for BPC-157 and Cartalax to guide experimental design decisions.
- Primary Mechanism
- Angiogenesis, VEGF/FGF upregulation, NO pathway modulation
- Gene expression normalization, ribosomal RNA synthesis, protein regulation
- BPC-157 for structural repair models; Cartalax for aging/senescence studies
- Molecular Weight
- 1419 Da (15 amino acids)
- 217 Da (2 amino acids)
- Cartalax's smaller size may enable better tissue penetration but offers less target specificity
- Typical Dosing (rodent)
- 200–500 μg daily or twice daily
- 10–100 μg per cycle (10 days on, 2–3 months off)
- BPC-157 requires continuous dosing; Cartalax uses pulsed intervention
- Half-Life Estimate
- 4–8 hours (biological activity duration)
- 2–4 hours (plasma), gene effects persist weeks
- Cartalax's transcriptional changes outlast peptide presence
- Reconstitution Solubility
- High (up to 5 mg/mL in water or saline)
- Moderate (2 mg/mL, pH 7.4–8.0 optimal)
- BPC-157 more forgiving in reconstitution protocols
- Post-Reconstitution Stability
- 28–30 days at 2–8°C
- 14–21 days at 2–8°C
- Cartalax requires faster use or aliquoting strategy
- Optimal Research Models
- Tendon/ligament injury, gastric ulcers, IBD, ischemia-reperfusion
- Cellular senescence, immune aging, organ bioregulation, lifespan studies
- Choose based on research endpoint: tissue healing vs cellular regulation
- Route of Administration
- Subcutaneous, intraperitoneal, oral (some models)
- Subcutaneous, intramuscular
- BPC-157's acid stability enables oral delivery research
- Published Evidence Base
- 200+ studies (PubMed indexed), primarily Eastern European research
- 80–100 studies, mostly Russian/Eastern European research
- BPC-157 has broader international research presence
- Cost Per Research Dose
- $3–8 per 500 μg dose (varies by supplier)
- $5–12 per 100 μg dose
- Cartalax often more expensive per milligram due to specialized synthesis demand